$5.07 Billion is the total value of Eventide Asset Management's 143 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NEP | NEXTERA ENERGY PARTNERS LP | $102,201,173 | -3.1% | 1,458,142 | 0.0% | 2.02% | -2.8% | |
| KRTX | KARUNA THERAPEUTICS INC | $102,121,050 | -12.6% | 519,700 | 0.0% | 2.01% | -12.4% | |
| EXAS | EXACT SCIENCES CORP | $92,453,241 | +52.4% | 1,867,365 | 0.0% | 1.82% | +52.7% | |
| POOL | POOL CORP | $74,705,743 | -5.0% | 247,100 | 0.0% | 1.47% | -4.8% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $61,006,558 | +44.8% | 2,629,593 | 0.0% | 1.20% | +45.1% | |
| GH | GUARDANT HEALTH INC | $45,723,200 | -49.5% | 1,681,000 | 0.0% | 0.90% | -49.3% | |
| BEP | BROOKFIELD RENEWABLE PARTNERpartnership unit | $31,320,240 | -19.0% | 1,236,000 | 0.0% | 0.62% | -18.8% | |
| XENE | XENON PHARMACEUTICALS INC | $25,282,516 | +9.2% | 641,200 | 0.0% | 0.50% | +9.7% | |
| BCYC | BICYCLE THERAPEUTICS PLCsponsored ads | $25,272,480 | +27.3% | 853,800 | 0.0% | 0.50% | +27.4% | |
| HASI | HANNON ARMSTRONG SUST INFR C | $23,840,803 | -3.2% | 822,664 | 0.0% | 0.47% | -2.9% | |
| BEPC | BROOKFIELD RENEWABLE CORPcl a sub vtg | $21,344,023 | -15.7% | 775,019 | 0.0% | 0.42% | -15.5% | |
| RGEN | REPLIGEN CORP | $20,147,890 | -9.5% | 119,000 | 0.0% | 0.40% | -9.4% | |
| ISRG | INTUITIVE SURGICAL INC | $19,901,250 | +41.6% | 75,000 | 0.0% | 0.39% | +41.5% | |
| BPMC | BLUEPRINT MEDICINES CORP | $19,210,685 | -33.5% | 438,500 | 0.0% | 0.38% | -33.3% | |
| ANNX | ANNEXON INC | $18,749,046 | -16.3% | 3,626,508 | 0.0% | 0.37% | -16.1% | |
| ESI | ELEMENT SOLUTIONS INC | $17,662,490 | +11.8% | 971,000 | 0.0% | 0.35% | +11.9% | |
| APLS | APELLIS PHARMACEUTICALS INC | $17,548,047 | -24.3% | 339,355 | 0.0% | 0.35% | -24.1% | |
| AESC | AES CORPunit 02/15/2024 | $17,464,112 | +15.4% | 171,200 | 0.0% | 0.34% | +15.4% | |
| VCYT | VERACYTE INC | $17,370,360 | +43.0% | 732,000 | 0.0% | 0.34% | +43.5% | |
| NOVT | NOVANTA INC | $17,106,033 | +17.5% | 125,900 | 0.0% | 0.34% | +17.8% | |
| PNR | PENTAIR PLC | $15,760,992 | +10.7% | 350,400 | 0.0% | 0.31% | +11.1% | |
| SYY | SYSCO CORP | $13,539,295 | +8.1% | 177,100 | 0.0% | 0.27% | +8.5% | |
| ROIVANT SCIENCES LTD | $13,505,497 | +153.4% | 1,690,300 | 0.0% | 0.27% | +153.3% | ||
| EHC | ENCOMPASS HEALTH CORP | $11,632,746 | +32.2% | 194,495 | 0.0% | 0.23% | +32.4% | |
| NTLA | INTELLIA THERAPEUTICS INC | $11,129,910 | -37.7% | 319,000 | 0.0% | 0.22% | -37.6% | |
| BEAM | BEAM THERAPEUTICS INC | $10,443,348 | -17.9% | 267,025 | 0.0% | 0.21% | -17.6% | |
| BAX | BAXTER INTL INC | $10,122,642 | -5.4% | 198,600 | 0.0% | 0.20% | -4.8% | |
| ALXO | ALX ONCOLOGY HLDGS INC | $10,165,540 | +17.8% | 902,000 | 0.0% | 0.20% | +17.6% | |
| ICPT | INTERCEPT PHARMACEUTICALS IN | $9,896,000 | -11.3% | 800,000 | 0.0% | 0.20% | -11.4% | |
| GXO LOGISTICS INCORPORATED | $9,391,800 | +21.8% | 220,000 | 0.0% | 0.18% | +21.7% | ||
| MRTX | MIRATI THERAPEUTICS INC | $9,225,116 | -35.1% | 203,600 | 0.0% | 0.18% | -35.0% | |
| PRAX | PRAXIS PRECISION MEDICINES I | $8,372,988 | +4.8% | 3,518,062 | 0.0% | 0.16% | +5.1% | |
| SWAV | SHOCKWAVE MED INC | $8,162,717 | -26.1% | 39,700 | 0.0% | 0.16% | -25.8% | |
| ELS | EQUITY LIFESTYLE PPTYS INC | $7,970,671 | +2.8% | 123,385 | 0.0% | 0.16% | +2.6% | |
| WD | WALKER & DUNLOP INC | $7,419,107 | -6.3% | 94,535 | 0.0% | 0.15% | -6.4% | |
| ADCT | ADC THERAPEUTICS SA | $7,219,043 | -20.3% | 1,879,959 | 0.0% | 0.14% | -20.2% | |
| ARE | ALEXANDRIA REAL ESTATE EQ IN | $4,710,239 | +3.9% | 32,335 | 0.0% | 0.09% | +4.5% | |
| IONS | IONIS PHARMACEUTICALS INC | $4,154,700 | -14.6% | 110,000 | 0.0% | 0.08% | -14.6% | |
| XPO | XPO INC | $3,828,350 | -25.2% | 115,000 | 0.0% | 0.08% | -25.7% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $1,867,112 | -53.4% | 276,200 | 0.0% | 0.04% | -53.2% | |
| TALS | TALARIS THERAPEUTICS INC | $1,592,314 | -61.2% | 1,561,092 | 0.0% | 0.03% | -61.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
About Eventide Asset Management
Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.
The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.
The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.
Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.
Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LOWES COS INC | 40 | Q3 2023 | 3.2% |
| PALO ALTO NETWORKS INC | 40 | Q3 2023 | 3.6% |
| ASML HOLDINGS NV | 40 | Q3 2023 | 1.9% |
| NEUROCRINE BIOSCIENCES INC | 40 | Q3 2023 | 1.1% |
| REPLIGEN CORP | 40 | Q3 2023 | 0.5% |
| VERACYTE INC | 38 | Q3 2023 | 1.5% |
| LAM RESEARCH CORP | 35 | Q3 2023 | 3.4% |
| XPO LOGISTICS INC | 34 | Q1 2023 | 3.8% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.6% |
| MAGNA INTL INC | 33 | Q4 2021 | 2.5% |
View Eventide Asset Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | February 14, 2023 | 2,589,778 | 3.7% |
| ESSA Pharma Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Freeline Therapeutics Holdings plc | February 14, 2023 | 5,920,765 | 9.1% |
| KnowBe4, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Praxis Precision Medicines, Inc. | February 14, 2023 | 3,518,062 | 7.5% |
| Prometheus Biosciences, Inc. | February 14, 2023 | 1,032,938 | 2.2% |
| SUTRO BIOPHARMA, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Vital Farms, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Zymeworks Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Entasis Therapeutics Holdings Inc. | February 14, 2022 | 590,602 | 1.2% |
View Eventide Asset Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Eventide Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.